logo-loader
viewAmryt Pharma PLC

Amryt Pharma unveils brand name for phase III cream for rare genetic skin disease

AP101, which is being developed to treat epidermolysis bullosa, will be launched commercially as FILSUVEZ

Amryt Pharma PLC -
Soothing cream: EB is a painful condition where skin blisters at the slightest touch

Amryt Pharma PLC (LON:AMYT) has taken another important step towards the global launch of its phase III treatment for the rare skin condition epidermolysis bullosa (EB) by announcing its brand name.

AP101 will be launched commercially as FILSUVEZ.

“This, alongside our recent completion of recruitment into the EASE study, represents further progress as we endeavour to develop a therapy for patients with EB, a rare and distressing genetic skin disorder affecting young children and adults for which there is currently no approved treatment," Amryt chief executive, Dr Joe Wiley said in a statement.

The top-line read-out from phase III EASE clinical trial is expected towards the end of the third quarter, or early Q4, Amryt has previously guided.

EB is a painful condition where skin blisters at the slightest touch. As there is currently no approved treatment, FILSUVEZ has fast-track status with the US regulatory authorities.

The company estimates the potential US and European market for FILSUVEZ to be worth in excess of US$1bn.

Quick facts: Amryt Pharma PLC

Price: 178.5 GBX

AIM:AMYT
Market: AIM
Market Cap: £275.78 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Amryt Pharma PLC named herein, including the promotion by the Company of Amryt Pharma PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Orphan drug status for new compound 'great news' says Amryt Pharma PLC's COO

Amryt Pharma PLC (LON:AMYT) has been granted orphan drug status in the US for  a compound called AP102 to treat patients with the excess growth condition acromegaly. Chief operating officer Rory Nealon tells Proactive: ''Our focus is to acquire, develop and commercialise products in the...

on 11/07/2016

2 min read